LifeMD
LFMD
Market cap $512M

11.26 USD

-0.70

5.85%

At close Jul 11, 4:00 PM EDT

After hours

11.28

+0.02

0.18%

1 day

-5.85%

5 days

-9.27%

1 month

-10.85%

3 months

123.86%

6 months

138.56%

Year to date

115.30%

1 year

79.87%

5 years

43.44%

10 years

43.44%

About: LifeMD Inc is a direct-to-patient telehealth company that provides a smarter, cost-effective, and more convenient way of accessing comprehensive, virtual healthcare. Its telehealth platform seamlessly integrates a clinician-centric electronic medical record (EMR) system, proprietary algorithms for case-load balancing and scheduling, customer relationship management functionality, remote and in-home lab testing, and digital prescription capabilities, patient-provider audio/video interfacing, cloud pharmacy fulfillment, and more. In addition to telehealth offerings, the company sells nutritional supplements and other over-the-counter products. The company has two operating segments: Telehealth and WorkSimpli. The company generates the majority of its revenue from the Telehealth segment.

Employees: 336

Healthcare Health Information Services

0

Funds holding %

of 7,312 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

22% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 32

13% more capital invested

Capital invested by funds: $79.3M [Q4 2024] → $89.7M (+$10.3M) [Q1 2025]

0.03% less ownership

Funds ownership: 37.01% [Q4 2024] → 36.98% (-0.03%) [Q1 2025]

3% less funds holding

Funds holding: 105 [Q4 2024] → 102 (-3) [Q1 2025]

11% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 19

70% less call options, than puts

Call options by funds: $1.1M | Put options by funds: $3.68M

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$14

24%

upside

Avg. target

$16

42%

upside

High target

$18

60%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

Lake Street Brooks O'Neil	60%upside $18	Buy Maintained	10 Jul 2025
HC Wainwright & Co. Yi Chen	24%upside $14	Buy Reiterated	30 Apr 2025

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about LFMD published over the past 30 days

Zacks Investment Research

Hims & Hers vs. LifeMD: Which Telehealth Stock Has More Upside?

HIMS and LFMD are surging in the telehealth race, but which one has stronger earnings growth and expansion momentum? Let's see.

Hims & Hers vs. LifeMD: Which Telehealth Stock Has More Upside?

The Motley Fool

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving.

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

LifeMD: Inflection Into Profitability Should Drive Stock Upward

LifeMD is a fast-growing, profitable telehealth company with strong partnerships, a robust tech stack and a valuable SaaS asset. The Novo Nordisk/Hims fallout is bullish, not bearish, for LifeMD. Novo Nordisk and Eli Lilly are unlikely to break a partnership with LifeMD. Q1 2025 results showed an excellent inflection into profitability, but guidance was conservative and gross margins declined due to product mix.

LifeMD: Inflection Into Profitability Should Drive Stock Upward

LifeMD: An Overlooked GLP-1 Beneficiary

LifeMD has evolved through multiple rebrandings, now offering 24/7 virtual primary and urgent care access to patients. The company operates RexMD, a men's telehealth platform, serving around 500,000 customers with specialty health products. LifeMD owns a majority stake in WorkSimpli, which delivers high-margin, recurring revenue through digital workplace services like PDFSimpli and ResumeBuild.

LifeMD: An Overlooked GLP-1 Beneficiary

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share.

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

LifeMD to Participate in Two Investor Conferences During June

NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of June: BTIG Obesity Health Forum, June 18. Management will participate in a virtual panel discussion titled “Direct to Consumer vs.

LifeMD to Participate in Two Investor Conferences During June

LifeMD: Growth, Growth, And More Growth

LifeMD is experiencing a major growth inflection, with record Q1 revenue, first-ever GAAP profitability, and strong subscriber and margin gains. Multiple growth drivers - including GLP-1 programs, Medicare expansion, AI automation, and a women's health acquisition - support a robust multi-year growth outlook. Valuation is high on earnings metrics but discounted on sales multiples. Significant upside exists if LifeMD sustains revenue growth and achieves positive EPS.

LifeMD: Growth, Growth, And More Growth

Top 2 Health Care Stocks That May Implode In Q2

As of May 23, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 2 Health Care Stocks That May Implode In Q2

LifeMD Collaborates with Novo Nordisk to Launch $299 Introductory Bundle for Self-Pay Patients Prescribed Wegovy®

Bundled Offer Includes Wegovy® at $199 and LifeMD's Virtual Weight Loss Program for a Total First-Month Cost of $299, $599 per Month Thereafter Bundled Offer Includes Wegovy® at $199 and LifeMD's Virtual Weight Loss Program for a Total First-Month Cost of $299, $599 per Month Thereafter

LifeMD Collaborates with Novo Nordisk to Launch $299 Introductory Bundle for Self-Pay Patients Prescribed Wegovy®

LifeMD to Participate in Three Investor Conferences During May

NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of May:

LifeMD to Participate in Three Investor Conferences During May

See News Rankings

Charts implemented using Lightweight Charts™